Background
==========

Paraquat (PQ) is a non-selective and fast-acting contact herbicide which has been widely used in developing countries \[[@b1-medscimonit-22-1342],[@b2-medscimonit-22-1342]\]. However, PQ is highly toxic to humans and animals. PQ poisoning has become a clinical challenge due to the lack of specific antidote or effective treatment \[[@b3-medscimonit-22-1342]\]. In recent decades, there have been numerous fatalities caused by accidental or voluntary ingestion of PQ \[[@b4-medscimonit-22-1342],[@b5-medscimonit-22-1342]\].

A variety of parameters has been suggested to predict clinical outcome after ingestion of PQ, including plasma and urine PQ concentrations, urinary PQ qualitative test, liver enzymes, serum creatinine, arterial blood bicarbonate, leukocytosis, angiopoietin, and acidosis \[[@b6-medscimonit-22-1342]--[@b14-medscimonit-22-1342]\]. In addition, severity scoring systems such as sequential organ failure assessment (SOFA), acute physiology and chronic health evaluation II (APACHE II), simplified acute physiology score II (SAPS II), and severity index for paraquat poisoning (SIPP) have been proposed as disease progression predictors \[[@b15-medscimonit-22-1342]--[@b19-medscimonit-22-1342]\]. The extent of lung injury in CT and pulmonary emphysema have also been claimed to correlate with the prognosis of PQ poisoning \[[@b20-medscimonit-22-1342],[@b21-medscimonit-22-1342]\]. Although much effort has been expended in exploring effective predictors, most of those potential predictors have not been independently validated, and some of the indicators have proven to be too complex or unfavorable for early prediction \[[@b10-medscimonit-22-1342],[@b12-medscimonit-22-1342]\]. Therefore, further efforts are warranted to develop reliable predictors for prognosis in PQ poisoning and to guide future clinical interventions.

The main sources of amylase are the pancreas and salivary glands. Serum amylase is typically used as confirm or exclude the diagnosis of pancreatitis and salivary glands disease. However, increase in serum level of amylase frequently occurs in other conditions, such as in patients with shock, trauma, hypoxemia, kidney damage, and acute liver failure \[[@b22-medscimonit-22-1342]--[@b24-medscimonit-22-1342]\]. Hyperamylasemia was also reported to occur in patients with PQ poisoning \[[@b10-medscimonit-22-1342],[@b25-medscimonit-22-1342],[@b26-medscimonit-22-1342]\]. Here, we report the predictive value and clinical characteristics of hyperamylasemia in patients with PQ poisoning.

Material and Methods
====================

The protocol of this study was approved by the Shanghai Tenth People's Hospital of Tongji University Institutional Review Board (IRB: 2012RES045).

Patients
--------

We reviewed the medical records of patients admitted to Shanghai Tenth People's Hospital with acute PQ poisoning from July 2012 to May 2015. During this period, 102 patients with PQ poisoning were admitted to this hospital; 87 patients were included in our research eventually according to the inclusion criteria and exclusion criteria ([Figure 1](#f1-medscimonit-22-1342){ref-type="fig"}). Inclusion criteria were: (1) the patient's age between 15 to 65 years old, and (2) plasma or urine PQ concentration exceeding 0.1 mg/L. Exclusion criteria were: (1) previous diagnosis of the following diseases: patients with history of pancreatic disease, renal function impairment, symptomatic biliary stones, or chronic hepatitis; (2) patients with a history of alcoholism; (3) patients without serum amylase measurement; and (4) interval between PQ ingestion and hospital admission \>48 h.

Data collection
---------------

Demographic data, medical histories, nausea and vomiting, stomach ache, quantity of PQ ingested, time from PQ poisoning to treatment, and APACHE II and SOFA scores were collected. APACHE II and SOFA scores were based on the worst condition within the first 24 h of admission. Clinical laboratory tests completed during 24 h of hospitalization were collected, including measurements of serum amylase, plasma and urine PQ concentrations, CRP, glucose, Ca^2+^, routine blood test, blood gas analysis, serum creatinine (SCr), blood urea nitrogen (BUN), aspartate aminotransferase (AST), and alanine aminotransferase (ALT). Abdominal CT scan reports were recorded when available. The primary outcome measure was the occurrence of death within 90 days after PQ ingestion.

Treatment protocol
------------------

All patients received standard of care treatment, as described in our previous study \[[@b20-medscimonit-22-1342],[@b21-medscimonit-22-1342]\]. In brief, all subjects admitted to the Emergency Department were treated with gastric lavage and activated charcoal. After that, charcoal hemoperfusion or continuous renal replacement therapy (CRRT) was performed if needed. Other treatment modalities such as methylprednisolone pulse treatment, prevention and treatment of infection, and protection of vital organs were implemented as clinically warranted.

Definition
----------

Toxic hepatitis was defined as having either AST or ALT \>80 IU/L (twice the upper normal limits) or a total bilirubin level \>36.6 umol/L \[[@b27-medscimonit-22-1342]\]. Hypoxemia was defined as PaO2 \<70 mmHg \[[@b27-medscimonit-22-1342]\]. Acute kidney injury (AKI) was diagnosed based on the KDIGO criteria (increase in serum creatinine by ≥0.3 mg/dl (≥26.5 μmol/l) within 48 h or an increase in serum creatinine to ≥1.5 times baseline within the preceding 7 days) \[[@b28-medscimonit-22-1342]\]. Hyperamylasemia was defined as having serum amylase levels greater than the normal levels (\>220U/L). Diagnosis of acute pancreatitis requires 2 of the following 3 features: (1) upper abdominal pain of acute onset often radiating through to the back, (2) serum amylase or lipase activity greater than 3 times normal, and (3) positive abdominal CT results \[[@b29-medscimonit-22-1342],[@b30-medscimonit-22-1342]\].

Statistical analysis
--------------------

Univariate analysis was performed with nonparametric test to evaluate differences in continuous variables and the chi-square test was used for comparing distributions among groups. To estimate hazard ratios and the resulting 95% confidence intervals (CIs) of predictors of in-hospital mortality, a forward stepwise Cox proportional hazards model was used. Survival curves were estimated using the Kaplan-Meier method and were compared using the log-rank test. Receiver operating characteristic (ROC) analysis was used to study the discriminatory power of serum amylase with respect to 90-day mortality. All tests were 2-tailed; *p* values \<0.05 were considered to indicate statistical significance. Data were analyzed using SPSS version 20.0 for Microsoft Windows (SPSS, Inc., Chicago, IL, USA).

Results
=======

Patient characteristics
-----------------------

A total of 87 patients with PQ poisoning (36 men and 51 women) were included in this study. Overall 90-day mortality was 41.4% (36 of 87). We divided patients into 2 groups in accordance with serum amylase levels ("non-elevation group" and "elevation group"); 29 Patients had elevated serum amylase in this study ([Figure 1](#f1-medscimonit-22-1342){ref-type="fig"}). Univariate analysis identified that time to hospital after ingestion time (*p*=0.020), estimated PQ amount (*p*\<0.001), APACHE II (*p*\<0.001) and SOFA (*p*\<0.001) scores, and mortality rate (*p*=0.001) were significantly higher in patients with hyperamylasemia (in the elevation group in [Table 1](#t1-medscimonit-22-1342){ref-type="table"}). In contrast, there were no significant differences in age and sex between the non-elevation group and elevation group. Stomach ache was also found to be similar in the 2 groups.

Association between serum amylase and laboratory parameters of PQ poisoning
---------------------------------------------------------------------------

Next, we compared the laboratory parameters between the serum amylase elevation group and serum amylase non-elevation group. Plasma PQ concentration (*p*=0.001), urine PQ concentration (*p*=0.001), CRP (*p*\<0.001), WBC (*p*\<0.001), SCr (*p*\<0.001), AST (*p*\<0.001), ALT (*p*\<0.001), and PaCO2 (*p*=0.001) were significantly increased in patients with hyperamylasemia. In addition to the above variables, other laboratory parameters such as glucose and Ca^2+^ did not show any significant difference ([Table 1](#t1-medscimonit-22-1342){ref-type="table"}).

Risk factor analysis for 90-day mortality
-----------------------------------------

In the univariate Cox proportional hazard regression model, we used age, sex, time to hospital, estimated PQ amount, serum amylase, SOFA scores, APACHE II scores, and plasma and urine PQ concentrations as independent variable. This analysis confirmed that the estimated PQ amount (*p*\<0.001), serum amylase (*p*\<0.001), SOFA scores (*p*\<0.001), APACHE II scores (*p*\<0.001), and plasma (*p*\<0.001) and urine (*p*\<0.001) PQ concentrations were all significantly associated with 90-day mortality. Next, a forward stepwise multiple Cox proportional hazards model indicated that the probability of mortality increased with serum amylase (hazard ratio \[HR\]=3.644; 95% \[CI\], 1.684--7.881; *p*=0.001), APACHE II scores (3.518; 1.310--9.446; 0.013) and plasma PQ concentration (4.296; 2.164--8.528; 0.004) ([Table 2](#t2-medscimonit-22-1342){ref-type="table"}). [Table 2](#t2-medscimonit-22-1342){ref-type="table"} indicates that serum amylase was independently associated with an increased risk of death. A log-rank test further confirmed that hyperamylasemia was associated with higher 90-day mortality (95% \[CI\], 14.100--43.495; *p*\<0.001) ([Figure 2](#f2-medscimonit-22-1342){ref-type="fig"}).

ROC analysis
------------

We calculated the areas under ROC curve of plasma PQ concentration, urinary PQ concentration, serum amylase, serum creatinine, and APACHE II and SOFA scores to compare the discriminatory capacities of these parameters in predicting 90-day mortality. The area under the ROC curve for serum amylase (area under curve \[AUC\]=0.837; 95% \[CI\], 0.750--0.923) exhibited better discriminatory potential than plasma PQ concentration (0.679; 0.562--0.796) or urinary PQ concentration (0.647; 0.528--0.766), although it had predictive potential similar to APACHE II (0.845; 0.765--0.925) and SOFA (0.867; 0.790--0.943) scores ([Figure 3](#f3-medscimonit-22-1342){ref-type="fig"}).

Association between serum amylase and organ damage in PQ poisoning
------------------------------------------------------------------

Among the patients with hyperamylasemia, 25 of 29 (86.2%) patients developed AKI (*p*\<0.001), while 20 of 29 (69.0%) patients exhibited hepatotoxicity (*p*=0.000) ([Table 1](#t1-medscimonit-22-1342){ref-type="table"}). Indeed, the serum amylase levels were significantly higher among patients with AKI compared to those without AKI ([Figure 4](#f4-medscimonit-22-1342){ref-type="fig"}). Hypoxemia and acidosis showed no significant difference between the 2 groups ([Table 1](#t1-medscimonit-22-1342){ref-type="table"}). Only 1 patient (3.4%) was diagnosed with PQ-associated painless acute pancreatitis (data not shown).

Discussion
==========

In the present study, univariate analysis indicated that patients with hyperamylasemia exhibited higher plasma level of PQ, urinary level of PQ, estimated PQ amount, and APACHE II and SOFA scores. Hyperamylasemia was also correlated with mortality and the severity of AKI and toxic hepatitis ([Table 1](#t1-medscimonit-22-1342){ref-type="table"}). Our study agrees well with previous studies that elevated amylase activity is a significant predictor of survival in PQ poisoning \[[@b10-medscimonit-22-1342],[@b25-medscimonit-22-1342],[@b31-medscimonit-22-1342]\]. These findings suggest that hyperamylasemia could be used as a valuable and objective predictive parameter for mortality in PQ poisoning.

Li et al. found that amylase is an independent prognostic marker, and the ROC curve showed serum amylase has a good power in the prediction of the death \[[@b26-medscimonit-22-1342]\]. Our study was consistence with theirs ([Table 2](#t2-medscimonit-22-1342){ref-type="table"}). However, in the present study we further compared the predictive power of amylase with plasma and urine concentrations of paraquat, and found that the discriminatory power of serum amylase in our study was much better than plasma and urine PQ concentration ([Figure 3](#f3-medscimonit-22-1342){ref-type="fig"}).

Plasma and urine concentrations have been regarded as effective parameters for prediction of clinical outcome following acute PQ poisoning \[[@b2-medscimonit-22-1342],[@b7-medscimonit-22-1342],[@b8-medscimonit-22-1342]\]. However, these have been questioned, as some studies found that plasma concentration was not as reliable as reported \[[@b32-medscimonit-22-1342],[@b33-medscimonit-22-1342]\]. The mortality predictive powers of plasma and urine PQ concentrations were relatively low in our study. This may be explained by the following: (1) serum paraquat distributes to other organs quickly and decreases rapidly within the first few hours after ingestion. During this period, the plasma PQ concentration varies substantially even with slight changes in the time interval following ingestion \[[@b32-medscimonit-22-1342]\]. (2) In the present study, the time interval between ingestion and serum PQ measurement was quite variable between the patients; thus, the varying or increased time-to-hospital interval after PQ ingestion may account for the observation that plasma PQ concentrations are not predictive of outcome. (3) PQ is primarily eliminated through the kidneys, and renal excretion of PQ is decreased when renal function is compromised \[[@b32-medscimonit-22-1342]\]. Indeed, AKI occurred in 52 of 87 patients (59.8%), and this may have influenced the predictive capacity of urine PQ concentrations. (4) Charcoal hemoperfusion was initiated if the urine dithionite test was positive in PQ-poisoned patients. Thus, the initial management with charcoal hemoperfusion in PQ poisoning may also account for the observation that blood and urine PQ concentrations were not predictive of outcome in the present study.

In our study, 29 of 87 patients (33.3%) exhibited hyperamylasemia and more than half of them exhibited 3-fold or higher increases. Of these, 1 of 29 (3.4%) patients were diagnosed with PQ-associated painless mild acute pancreatitis and eventually died. A previous study on PQ poisoning reported that mild acute pancreatitis occurred in 1 out of 8 PQ-poisoned autopsy cases \[[@b34-medscimonit-22-1342]\]. It is possible that hyperamylasemia may reflect clinical acute pancreatitis in a small number of cases. Taking into account that elevations of non-pancreatic amylase have been reported in a large number of pathologies, there may have been some other causes of elevated serum amylase in PQ-poisoned patients.

Some earlier studies suggested that the reason for increased serum levels of serum amylase may be due to a decreased rate of excretion into the urine, rather than direct pancreatic cellular damage \[[@b35-medscimonit-22-1342]\], such as in cardiovascular surgery \[[@b36-medscimonit-22-1342]\]. It has been reported that about 25% of serum amylase is excreted by the kidneys \[[@b37-medscimonit-22-1342]\]. Kidney injury can decrease the excretion of serum amylase and this has been associated with elevation of pancreatic isoamylase \[[@b38-medscimonit-22-1342],[@b39-medscimonit-22-1342]\]. Unfortunately, early deterioration of renal function is a critical complication in acute PQ poisoning \[[@b40-medscimonit-22-1342],[@b41-medscimonit-22-1342]\]. There were 25 of the 29 patients (86.2%) with hyperamylasemia combined with AKI in our study. Serum amylase was significantly higher among patients with AKI than those without AKI ([Figure 4](#f4-medscimonit-22-1342){ref-type="fig"}). These findings raise the possibility that AKI may be an important cause of elevated serum amylase in PQ-poisoned patients.

Pancreatic damage secondary to acute hepatic failure has been described in many reports \[[@b42-medscimonit-22-1342]--[@b44-medscimonit-22-1342]\]. Toxic hepatitis occurred in 25 of 87 patients (28.7%) in our study; only 1 of them progressed to acute hepatic failure and showed no evidence of hyperamylasemia. Hence, toxic hepatitis was not a common cause for the hyperamylasemia observed in our study. Other potential causes of elevated amylase, such as hypoxemia, have been observed in other studies \[[@b24-medscimonit-22-1342]\]. However, hypoxemia was not different among PQ-poisoned patients with hyperamylasemia compared to those with normal values ([Table 1](#t1-medscimonit-22-1342){ref-type="table"}), indicating that hypoxemia was not causing the hyperamylasemia observed in PQ-poisoned patients.

The hyperamylasemia in PQ poisoning also may also originate from cell injury in other organs, such as salivary glands and the intestines. In addition, although only a minority of PQ-poisoned patients were diagnosed with clinically acute pancreatitis, PQ-induced subclinical pancreatic damage could not be excluded. Pancreatic amylase (P-Amy) and the salivary amylase(S-Amy) are 2 specific amylase isoenzymes \[[@b45-medscimonit-22-1342]\]. P-Amy has a better sensitivity and specificity than total serum amylase for diagnosing acute pancreatitis \[[@b46-medscimonit-22-1342]\], which will be monitored in this laboratory in the future.

Conclusions
===========

Serum amylase is frequently elevated in PQ-poisoned patients, although its mechanism remains to be established. Hyperamylasemia is an early and valuable predictor for 90-day mortality in PQ poisoning, and this is a simpler and more objective test compared to the APACHE II or SOFA scores.
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###### 

General characteristics and laboratory data within 24h following admission.

  Characteristic                           Non-elevation group (n=58)   Elevation group (n=29)   P value
  ---------------------------------------- ---------------------------- ------------------------ ---------
  Age, year                                34.4±2.6                     37.8±4.6                 0.643
  Male/Female, n                           28/30                        8/21                     0.065
  Time to hospital after ingestion, hour   24 (1--267)                  13 (6--108)              0.020
  Estimated PQ amount, ml                  15 (2--120)                  60 (10--200)             0.000
  Hemoperfusion, n                         39 (67)                      23 (79)                  0.241
  Nausea and vomiting, n (%)               13 (22)                      15 (52)                  0.006
  Stomachache, n (%)                       11 (19)                      6 (21)                   0.848
  SOFA                                     2 (0--9)                     6 (1--12)                0.000
  APACHE II                                2 (0--14)                    9 (1--24)                0.000
  Nonsurvivors, n (%)                      12 (21)                      24 (83)                  0.000
  Plasma PQ concentration, mg/L            0.01 (0.01--22.28)           0.49 (0.01--408.10)      0.001
  Urine PQ concentration, mg/L             2.08 (0.01--248.72)          35.58 (0.01--2762.10)    0.001
  CRP                                      3.5 (0.4--68.0)              19.7 (0.5--126.0)        0.000
  Glucose                                  6.1 (2.1--21.6)              7.6 (2.9--17.4)          0.054
  Ca^2+^                                   2.3 (1.8--3.0)               2.3 (1.4--3.0)           0.939
  Routine blood test                                                                             
   WBC                                     10.2 (4.2--29.3)             22.5 (10.6--46.4)        0.000
   Hb                                      128.0 (87.0--177.0)          4.0 (1.0--17.2)          0.811
   PLT                                     145.5 (40.0--363.0)          156.0 (33.0--306.0)      0.322
  Renal function                                                                                 
   AKI, n (%)                              27 (46.6)                    25 (86.2)                0.000
   BUN, mmol/L                             5.4 (0.5----55.9)            7.0 (1.9--40.3)          0.089
   SCr, umol/L                             93.8 (29.6--999.8)           172.0 (37.1--821,9)      0.000
  Liver function                                                                                 
   Toxic hepatitis, n (%)                  5 (8.6)                      20 (69.0)                0.000
   Serum AST, IU/L                         25.8 (7.9--328.5)            190.8 (12.0--705.1)      0.000
   Serum ALT, IU/L                         18.6 (4.9--562.1)            162.5 (6.0--1327.6)      0.000
  Arterial blood gases                                                                           
   Hypoxemia, n (%)                        8 (13.8)                     8 (27.6)                 0.146
   Acidosis, n (%)                         4 (6.9)                      6 (20.7)                 0.077
   PH                                      7.42 (7.20--7.50)            7.40 (7.21--7.54)        0.380
   PaO~2~, mmHg                            90.0 (37.0--131.0)           88.2 (30.0--187.0)       0.989
   PaCO~2~, mmHg                           37.7 (21.0--51.0)            31.0 (0.0--45.0)         0.001

PQ -- paraquat; APACHE -- Acute Physiology and Chronic Health Evaluation; SOFA -- Sequential Organ Failure Assessment; CRP -- C-reactive protein; WBC -- white blood cell; Hb -- hemoglobin; PLT -- platelet; AKI -- acute kidney injury; BUN -- blood urea nitrogen; SCr -- serum creatinine; AST -- aspartate aminotransferase; ALT -- alanine aminotransferase. Data are presented as means ±SD or median (interquartile range) and categorical variable is presented as no (%).

###### 

Cox proportional hazards models for mortality prediction in PQ poisoning.

                            Univariate COX Model    Multivariate COX Model                           
  ------------------------- ----------------------- ------------------------ ----------------------- -------
  Age                       1.000 (0.985--1.015)    0.959                    N/A                     N/A
  Gender                    0.974 (0.502--1.891)    0.849                    N/A                     N/A
  Time to hospital          0.999 (0.992--1.006)    0.849                    N/A                     N/A
  Estimated PQ amount       7.685 (3.343--17.667)   0.000                    N/A                     0.171
  Serum amylase             8.823 (4.336--17.954)   0.000                    3.644 (1.684--7.881)    0.001
  SOFA                      3.480 (1.754--6.904)    0.000                    3.465 (0.962--12.474)   0.057
  APACHE II                 3.639 (1.876--7.059)    0.000                    3.518 (1.310--9.446)    0.013
  Plasma PQ concentration   4.296 (2.164--8.528)    0.000                    2.714 (1.373--5.364)    0.004
  Urine PQ concentration    2.566 (1.278--5.153)    0.000                    N/A                     0.546

HR -- hazard ratio; N/A -- not applicable; SOFA -- Sequential Organ Failure Assessment; APACHE II -- Acute Physiology and Chronic Health Evaluation.
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